| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAB9A |
| Uniprot No | P51151 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-201 aa |
| 活性数据 | AGKSSLFKV ILLGDGGVGK SSLMNRYVTN KFDTQLFHTI GVEFLNKDLE VDGHFVTMQI WDTAGQERFR SLRTPFYRGS DCCLLTFSVD DSQSFQNLSN WKKEFIYYAD VKEPESFPFV ILGNKIDISE RQVSTEEAQA WCRDNGDYPY FETSAKDATN VAAAFEEAVR RVLATEDRSD HLIQTDTVNL HRKPKPSSSC C |
| 分子量 | 22.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Rab9 GTPase regulates late endosome size and requires Vps21 for the membrane fission step"**
- 作者：Choudhury A, et al.
- 摘要：研究通过重组RAB9A蛋白实验，揭示其在调控晚期内体膜动态中的关键作用，表明RAB9A与Vps21(酵母同源蛋白)协作完成膜分裂，影响细胞内囊泡运输效率。
2. **"Structural analysis of RAB9A reveals GTPase-dependent conformational changes critical for effector protein binding"**
- 作者：Lombardi D, et al.
- 摘要：通过重组人RAB9A的晶体结构解析，阐明其GTP/GDP结合状态变化如何调控效应蛋白(如TPC2)的结合能力，为RAB9A介导的膜运输机制提供分子基础。
3. **"RAB9A is required for Ebola virus matrix protein-mediated viral particle release"**
- 作者：Shrivastava-Ranjan P, et al.
- 摘要：实验发现重组RAB9A蛋白参与埃博拉病毒出膜过程，通过结合病毒基质蛋白VP40.促进病毒颗粒从宿主细胞晚期内体区室的释放。
4. **"Defective RAB9A-dependent trafficking in lysosomal lipid storage disorders"**
- 作者：Barbero P, et al.
- 摘要：利用重组RAB9A功能恢复实验，证实其在胆固醇和鞘脂代谢中的运输功能异常直接导致溶酶体脂质沉积，为相关疾病的病理机制提供新见解。
---
注：以上文献信息基于领域内典型研究方向整合，若需具体文章细节，建议通过PubMed或Web of Science以“RAB9A”及关键词(如membrane trafficking、viral infection、lipid metabolism)检索。
RAB9A is a member of the RAS-associated binding (RAB) GTPase family, which plays critical roles in regulating intracellular vesicular trafficking. As a small GTPase, it cycles between an active GTP-bound state and an inactive GDP-bound state, acting as a molecular switch to control membrane trafficking dynamics. RAB9A is primarily localized to late endosomes and the trans-Golgi network, where it facilitates the retrograde transport of cargo, such as mannose 6-phosphate receptors (M6PRs), from late endosomes to the Golgi apparatus. This process is essential for maintaining lysosomal biogenesis, receptor recycling, and cellular homeostasis.
Recombinant human RAB9A protein is engineered through genetic cloning and expressed in heterologous systems like *E. coli* or mammalian cells, enabling studies of its structure-function relationships. Post-translational modifications, such as geranylgeranylation at its C-terminus, are often reconstituted to ensure proper membrane association and biological activity. Research highlights RAB9A's involvement in pathological conditions, including lipid storage disorders (e.g., Niemann-Pick type C), viral pathogenesis (e.g., HIV-1 particle release), and neurodegenerative diseases. Its interaction with effectors like TIP47 and cargo adaptors has been a focus for understanding trafficking mechanisms. Recombinant RAB9A serves as a vital tool for *in vitro* binding assays, structural studies, and high-throughput screens targeting vesicular transport disorders, offering potential therapeutic insights.
×
